EZHIP and neoplasm: One study found that bi-thalamic H3-WT tumours with loss of H3K27me3 often harboured Epidermal Growth Factor Receptor (EGFR) mutations7, while another suggested Activin A Receptor Type 1 (ACVR1) might be co-mutated with EZHIP overexpression6.